PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsXeris Pharmaceuticals
Xeris Pharmaceuticals(XERS)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Loading
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Plot placeholder
Mock data
Subscribe for the real data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
KeveyisDichlorphenamide1982-01-01
Glaucoma
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Glucagon
healthy volunteers/patients
,
common cold
,
insulin resistance
,
hypersensitivity
,
liver diseases
,
diabetes complications
,
hypoglycemia
,
type 1 diabetes mellitus
,
overweight
,
hyperglycemia
,
glucose metabolism disorders
,
metabolic diseases
,
metabolic syndrome
,
endocrine system diseases
,
weight loss
,
chronic renal insufficiency
,
kidney diseases
,
cardiovascular diseases
,
left ventricular dysfunction
,
coronary artery disease
,
type 2 diabetes mellitus
,
diabetes mellitus
,
obesity
,
fatty liver
,
body weight
,
weight gain
,
glucose intolerance
,
non-alcoholic fatty liver disease
,
knee osteoarthritis
,
osteoarthritis
,
carcinoma
,
thyroid neoplasms
,
neuroendocrine carcinoma
,
papillary thyroid cancer
,
thyroid diseases
,
diabetic nephropathies
,
inflammation
,
pancreatitis
,
hyperlipidemias
,
peripheral nervous system diseases
,
diabetic neuropathies
Sodium chloride
pharmacokinetics
,
healthy volunteers/patients
,
liver diseases
,
hepatocellular carcinoma
,
liver neoplasms
,
pathologic processes
,
infertility
,
brain diseases
Insulin
healthy volunteers/patients
,
glycemic control
,
aggression
,
hypersensitivity
,
neoplasms
,
insulin resistance
,
carcinoma
,
colonic neoplasms
,
rectal neoplasms
,
squamous cell carcinoma of head and neck
,
squamous cell carcinoma
,
hyperinsulinism
,
neuroendocrine tumors
,
hypoglycemia
,
chronic renal insufficiency
,
kidney diseases
,
glucose metabolism disorders
,
metabolic diseases
,
endocrine system diseases
,
obesity
,
cardiovascular diseases
,
chronic obstructive pulmonary disease
,
asthma
,
sepsis
,
septic shock
,
shock
,
toxemia
,
overweight
,
weight gain
,
diabetes mellitus
,
type 2 diabetes mellitus
,
type 1 diabetes mellitus
,
hyperglycemia
,
schizophrenia
,
metabolic syndrome
,
gestational diabetes
,
myocardial infarction
,
infarction
,
inferior wall myocardial infarction
,
psychotic disorders
,
prediabetic state
,
disease progression
,
pancreatitis
,
patient participation
,
peripheral nervous system diseases
,
diabetic neuropathies
,
glucose intolerance
Viaject
healthy volunteers/patients
,
glycemic control
,
aggression
,
hypersensitivity
,
neoplasms
,
insulin resistance
,
carcinoma
,
colonic neoplasms
,
rectal neoplasms
,
squamous cell carcinoma of head and neck
,
squamous cell carcinoma
,
hyperinsulinism
,
neuroendocrine tumors
,
hypoglycemia
,
chronic renal insufficiency
,
kidney diseases
,
glucose metabolism disorders
,
metabolic diseases
,
endocrine system diseases
,
obesity
,
cardiovascular diseases
,
chronic obstructive pulmonary disease
,
asthma
,
sepsis
,
septic shock
,
shock
,
toxemia
,
overweight
,
weight gain
,
diabetes mellitus
,
type 2 diabetes mellitus
,
type 1 diabetes mellitus
,
hyperglycemia
,
schizophrenia
,
metabolic syndrome
,
gestational diabetes
,
myocardial infarction
,
infarction
,
inferior wall myocardial infarction
,
psychotic disorders
,
prediabetic state
,
disease progression
,
pancreatitis
,
patient participation
,
peripheral nervous system diseases
,
diabetic neuropathies
,
glucose intolerance
Pram9
diabetes mellitus
,
type 1 diabetes mellitus
Pancreatin
exocrine pancreatic insufficiency
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use